
B8011006
NCT04165317
JCP076
Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST)
Status:
Opening Soon

III
Phase

2nd+
Line of Therapy

Early Cancer
Disease Stage

Biomarker(s)
N/A
Investigational
Product
Sasanlimab (PF-06801591)
Anti-programmed cell death 1 (PD-1) receptor antibody
Treatment Arms
o Experimental Arm 1: PF-06801591 + BCG induction and maintenance
o Experimental Arm 2: PF-06801591 + BCG induction only
o Active Comparator: BCG induction and maintenance